» Articles » PMID: 35511431

The Innate Immune Response Following Multivalent Dengue Vaccination and Implications for Protection Against Dengue Challenge

Overview
Journal JCI Insight
Date 2022 May 5
PMID 35511431
Authors
Affiliations
Soon will be listed here.
Abstract

Understanding the immune response to dengue virus (DENV) is essential for developing a dengue vaccine that is protective against all 4 DENV serotypes. We evaluated the immune response after vaccination (live attenuated tetravalent dengue vaccine TV005 or trivalent admixture) and after challenge with DEN2Δ30 (Tonga/74) to better understand the importance of homotypic immunity in vaccine protection. Significant increases in IP-10 expression were observed following receipt of either the trivalent or tetravalent vaccine. After challenge, a large increase in IP-10 expression was observed in the placebo and trivalent admixture groups but not in the tetravalent vaccine group. MCP-1, IL-1RA, and MIP-1β exhibited a similar pattern as IP-10. These results demonstrate protective effects of trivalent and tetravalent vaccines against DENV and suggest that the tetravalent vaccine has a better protective effect compared with the trivalent admixture. We also explored the postvaccination and postchallenge immune response differences between Black and White participants. White participants responded to vaccine differently than Black participants; Black participants receiving trivalent and tetravalent vaccines responded strongly and White participants responded only transiently in trivalent group. In response to challenge, White participants elicited a stronger response than Black participants. These results may explain why White participants may have a more vigorous DENV immune response than Black participants, as reported in literature.

Citing Articles

TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies.

Pierce K, Durbin A, Walsh M, Carmolli M, Sabundayo B, Dickson D J Clin Invest. 2023; 134(3).

PMID: 37971871 PMC: 10836801. DOI: 10.1172/JCI173328.


Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art.

Pintado Silva J, Fernandez-Sesma A J Gen Virol. 2023; 104(3).

PMID: 36857199 PMC: 10228381. DOI: 10.1099/jgv.0.001831.


Recent updates on correlates of vaccine-induced protection.

Plotkin S Front Immunol. 2023; 13:1081107.

PMID: 36776392 PMC: 9912984. DOI: 10.3389/fimmu.2022.1081107.


The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature.

Pintado Silva J, Fenutria R, Bernal-Rubio D, Sanchez-Martin I, Hunziker A, Chebishev E Exp Biol Med (Maywood). 2023; 247(24):2201-2212.

PMID: 36734144 PMC: 9899989. DOI: 10.1177/15353702231151241.


Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients.

Klingler J, Lambert G, Bandres J, Emami-Gorizi R, Nadas A, Oguntuyo K iScience. 2022; 25(12):105608.

PMID: 36406863 PMC: 9666267. DOI: 10.1016/j.isci.2022.105608.

References
1.
Tahhan A, Hammadah M, Mohamed Kelli H, Kim J, Sandesara P, Alkhoder A . Circulating Progenitor Cells and Racial Differences. Circ Res. 2018; 123(4):467-476. PMC: 6202175. DOI: 10.1161/CIRCRESAHA.118.313282. View

2.
Thakur P, Chakravarti A, Aggarwal S, Uppal B, Bhalla P . Elevated levels of vascular endothelial growth factor in adults with severe dengue infection. Virusdisease. 2016; 27(1):48-54. PMC: 4758303. DOI: 10.1007/s13337-015-0296-2. View

3.
Kouri G, Guzman M, Bravo J, TRIANA C . Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ. 1989; 67(4):375-80. PMC: 2491263. View

4.
Kwissa M, Nakaya H, Onlamoon N, Wrammert J, Villinger F, Perng G . Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe. 2014; 16(1):115-27. PMC: 4116428. DOI: 10.1016/j.chom.2014.06.001. View

5.
Blaney Jr J, Matro J, Murphy B, Whitehead S . Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol. 2005; 79(9):5516-28. PMC: 1082773. DOI: 10.1128/JVI.79.9.5516-5528.2005. View